Tag Archives: comparative effectiveness

The pros and the cons of CER

27 Jan

CER or Comparative Effectiveness Research has its defenders and its contradictors.

But first of all, what is the CER?

CER typically products guidelines issued from the comparison of respective harms and benefits of medicines or techniques of cure already marketed and used routinely by health care providers.

Defenders argue that this is the core of an evidence based medicine. Guidelines will save a lot of money by showing the best way to cure efficiently.

Contradictors estimate that this is the best way to sterilise the research and the development of new molecules and new procedures of treatment given that guidelines strictly forbid practitioners to welcome new therapies. Since guidelines decide the best state of the art, why care givers should worry and take the risk to try new therapies?

Beside there is the question of the quality of CER and of its independence with regard of the pharmaceutical industry. We have to keep in mind that independence with regard of industry is not automatically a warrant of quality because industry possesses a real research and development capacity.

If you want to read more on the topic of CER:











comparative effectiveness research

25 Sep
Health care systems

Image via Wikipedia

Comparative effectiveness research is heavily debated in the US between those who believe in its capacity to enhance the quality of health care and those who see in it a mean used by government agencies to save (or cut) costs in health care. The blogger Kevin in two posts enlightens the second point of view:



The Pharmacy Benefits Manager and the Drug Company

5 Jul

The Pharmacy Benefit Manager Medco contracted with the French Drug company Sanofi. In the United States Medco covers for their behind the counter pharmaceutical prescriptions as many enrollees as the entire French population (65 Million people). The aim of this agreement is to conduct comparative effectiveness studies in the real world clinical settings before endorsing for new drugs. This constitutes an alliance of the payer  with the drug maker with an objective of Research and Development improvement.

%d bloggers like this: